There is a greater prevalence of data supporting biologics or pharmacotherapy with various forms of brain wave stimulation or modulation.
The data is available, with small patient numbers.
The reason there is not more data is because neither the Pharmacotherapy or device companies want the study for fear of one modality dominating the other.
The other concern is the cost to the healthcare system.
In both instances, there is a cost such as, gene therapy with new versions of deep brain stimulation. Is there greater value to both combined in nearly eliminating Neurological disorder symptoms? Yes.
The alternative is the status quo…generic medicines first.. brand products or a device next with improvement depending on the disease state.
The solution? Targeted gene therapy? Sure, as has been the case for the past 15 years with progressively improved results and a higher associated cost.
Some solutions? Is the gene therapy worth the investment? Or, are there receptor sites new to a current disease state upstream from the occurrence from onset?
As for combination therapy? Three things need to change with Stimulation: 1. True efficacy and not palliative care. 2. Less invasive 3. Less cost to the healthcare system.
If you would like to discuss more on this topic for us to present some data and suggestions, contact us.
Neurology Life Science Consulting
address goes here
info@pharmakonsult.com
+1234567890
